Search / Trial NCT06611033

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

Launched by MERCK SHARP & DOHME LLC · Sep 20, 2024

Trial Information

Current as of October 03, 2024

Not yet recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • The main inclusion criteria include but are not limited to the following:
  • * Is in good health before randomization
  • Exclusion Criteria:
  • * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination.
  • * Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0